HITV Lab

Call Us : +603-9010-3058
Email Us : This email address is being protected from spambots. You need JavaScript enabled to view it.

Thursday15 November 2018

The Star : Anti-Cancer application

Blogger

A Japanese physician and researcher has based his cancer treatment protocol on dendritic cells’ ability to enable selective and effective attack against tumour cells by the body’s own T cells.

SINCE the discovery of dendritic cells by Dr Ralph Steinman in 1973, much research has been carried out to elucidate the basic functional mechanism of dendritic cells.

Many medical research institutes and universities have conducted research in the use of dendritic cells in anti-cancer immunotherapy.

The ability of dendritic cells to enable selective and effective attack against tumour cells by T cells gave rise to great hopes that it would be an ideal cancer treatment.

Read more ...

New Straits Times : Hope for late-stage cancer patients

NST

KUALA LUMPUR : There is still hope for late-stage cancer patients as treatment that could help cure the disease is now available in the country.

The Human Initiated Therapeutic Vaccine (HITV) Therapy, previously available only in Japan, has been brought to Malaysia through the Mahameru International Medical Centre.

Dr Kenichiro Hasumi, founder and president of the Hasumi International Research Foundation, said HITV is an autologous (patient-derived) active cell-based immunotherapy.

He said a HITV study on 26 patients with different advanced cancers showed 80 per cent of the patients demonstrated a complete response to the initial treatment, while 50 per cent have remained disease-free.

Read more ...

Subcategories

HITV Lab

HITV Lab is involved in cell-based biotechnology medical applications with special focus on Dendritic Cell-Based Immunotherapy for cancer. HITV Lab is committed to support an international collaboration in the FDA clinical trial of HITV Therapy in late-stage cancer patients led by the University of Maryland, USA.

FacebookTwitterGoogle Bookmarks